Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

A Role for Interleukin-1 Alpha in the 1,25 Dihydroxyvitamin D3 Response in Mammary Epithelial Cells

  • Sophia L. Maund,

    Current address: Department of Urology, Stanford University School of Medicine, Stanford, California, United States of America

    Affiliation Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America

  • Lihong Shi,

    Affiliation Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America

  • Scott D. Cramer

    Affiliation Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America

A Role for Interleukin-1 Alpha in the 1,25 Dihydroxyvitamin D3 Response in Mammary Epithelial Cells

  • Sophia L. Maund, 
  • Lihong Shi, 
  • Scott D. Cramer


Breast cancer is the most common non-cutaneous malignancy in American women, and better preventative strategies are needed. Epidemiological and laboratory studies point to vitamin D3 as a promising chemopreventative agent for breast cancer. Vitamin D3 metabolites induce anti-proliferative effects in breast cancer cells in vitro and in vivo, but few studies have investigated their effects in normal mammary epithelial cells. We hypothesized that 1,25(OH)2D3, the metabolically active form of vitamin D3, is growth suppressive in normal mouse mammary epithelial cells. In addition, we have previously established a role for the cytokine interleukin-1 alpha (IL1α) in the anti-proliferative effects of 1,25(OH)2D3 in normal prostate cells, and so we hypothesized that IL1α is involved in the 1,25(OH)2D3 response in mammary cells. Evaluation of cell viability, clonogenicity, senescence, and induction of cell cycle regulators p21 and p27 supported an anti-proliferative role for 1,25(OH)2D3 in mammary epithelial cells. Furthermore, 1,25(OH)2D3 increased the intracellular expression of IL1α, which was necessary for the anti-proliferative effects of 1,25(OH)2D3 in mammary cells. Together, these findings support the chemopreventative potential of vitamin D3 in the mammary gland and present a role for IL1α in regulation of mammary cell proliferation by 1,25(OH)2D3.


Epidemiological and laboratory studies point to vitamin D3 as a promising chemopreventative agent for breast cancer [1-7]. Rigorous clinical studies are lacking, but increasing evidence highlights the importance of vitamin D3 in maintaining breast health [8-11]. Low serum 25(OH)D3 concentrations are correlated with an increased risk for breast cancer [3], and suboptimal serum 25(OH)D3 levels are associated with more aggressive breast tumors, worse prognostic markers, and a higher risk for breast cancer recurrence [12]. These findings support reports of increased breast cancer risk and decreased survival in patients deficient in vitamin D3, and they warrant further investigations into the specific contributions of vitamin D3 to breast health.

Mammary epithelial cells endogenously express 1 alpha-hydroxylase (1α-OHase, encoded by CYP27B1) and can therefore generate 1,25 dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active form of vitamin D3, from 25(OH)D3 in autocrine and paracrine manners [13], which supports a role for 1,25(OH)2D3 in mammary gland function and homeostasis [14]. The vitamin D receptor (VDR) is expressed in all cells of the mammary tissue and it is actively regulated during puberty and pregnancy; its levels increase 100-fold throughout lactation [15]. VDR-knockout mice exhibit excessive mammary epithelial proliferation and impaired apoptosis [15,16], and breast tumors with higher VDR expression are correlated with better patient prognosis [17]. Furthermore, CYP27B1 (which encodes the 1,25(OH)2D3 activating enzyme 1α-OHase) expression is slightly lower in invasive breast tumors, while CYP24A1 (which encodes the 1,25(OH)2D3 inactivating enzyme 24-hydroxylase) levels are increased in tumors compared to benign lesions [18]. These studies suggest that breast cancer is associated with deregulation of vitamin D3 signaling. These and other in vitro and in vivo studies support the protective effects of 1,25 (OH)2D3 against breast cancer development and progression [1,19,20].

We previously reported a novel role for interleukin-1 alpha (IL1α) in the anti-proliferative effects of 1,25(OH)2D3 in the prostate progenitor/stem cell (PrP/SC) [21]. IL1α is a multi-functional cytokine that is classically characterized as pro-inflammatory, but it has more recently been reported to regulate cell proliferation, differentiation, and senescence in a cell-type-dependent manner [22-38]. Furthermore, while secreted IL1α and membrane-bound IL1α contribute to inflammation and immune responses, intracellular IL1α is hypothesized to exert anti-proliferative and pro-differentiation effects [39]. IL1α is one of only two interleukins that contain a nuclear localization sequence [40]. The precise nuclear role(s) of IL1α is still unclear, but studies suggest that it can impact transcription through interaction with RNA processing machinery, histone acetyltransferases, and transcription factors [41-44].

IL1α expression or activity has not previously been studied in benign mammary cells, neither alone nor in response to 1,25(OH)2D3. The effects of IL1α and 1,25(OH)2D3 in mammary cells is relevant to the study of vitamin D3 in the chemopreventative setting. Here, we report that 1,25(OH)2D3 induces IL1α expression in normal mouse mammary epithelial cells (MMECs), and that IL1α contributes to the anti-proliferative effects of 1,25(OH)2D3 in these cells.

Materials and Methods

Ethics statement

This study was approved by the Wake Forest University School of Medicine Animal Care and Use Committee. The method of sacrifice was carbon dioxide inhalation followed by cervical dislocation.

Isolation and culture of mouse mammary epithelial cells

Normal MMECs were isolated from C57BL/6; 129/SVEV mice as described in detail in [45]. The isolated cells were primarily basal epithelial cells, and vitamin D receptor expression was confirmed by reverse-transcriptase PCR (data not shown). Cells were cultured in complete DMEM/F12 as described in [46], and experiments were performed between passages 20-30.

Antibodies and reagents

Antibodies: p21 and p27, Cell Signaling Technology (Danvers, MA, USA); IL1α and IL1RI, Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA); β-actin, Sigma Aldrich (St. Louis, MO, USA); AlexaFluor 488 anti-Rabbit, Invitrogen (Carlsbad, CA, USA). Reagents: 1,25(OH)2D3, BIOMOL international (Plymouth Meeting, PA, USA). When BIOMOL was integrated into Enzo Life Sciences, 1,25(OH)2D3 was purchased from Sigma Aldrich.


Procedures for immunoblotting protein lysates from cells grown in monolayer is described in detail elsewhere [46]. Immunoblot experiments were repeated at least once and densitometry was performed using ImageJ software.

Growth assays

Trypan blue exclusion assays were performed as described in [47]. Briefly, cells were plated at 1 x 104 cells per 35 mm culture dish (n = 3, 4, or 5 replicate preparations). The medium was replaced with experimental media 24 hrs after plating. When control cells reached 90% confluency, cells were collected, trypan blue was administered, and total and non-viable cells were counted. The mean number of viable cells per dish and percentages of viable cells were calculated and statistical significance was verified using ANOVA (critical value = 0.05) with post-hoc analysis by Fisher’s LSD test using the statistical software package NCSS 6.0.22.

Clonogenic assays

Clonogenic assays were performed as described in Barclay et al. [48]. Briefly, cells were plated at 250 cells per 60 mm culture dish (n = 3 replicate preparations) in experimental or control medium. Cells were fixed and stained with 0.1% crystal violet in 95% ethanol after 9 days. Colonies (defined as >50 cells) were counted and the total areas were calculated in pixels using Adobe Photoshop Elements. Statistical determinations were calculated by ANOVA with post-hoc analysis by Fisher’s LSD test using the statistical software package NCSS 6.0.22.

Quantitative real-time PCR analysis (qPCR)

RNA was isolated from MMECs treated in triplicate with vehicle (0.1% ethanol) or 100 nM 1,25(OH)2D3 for 24 hrs, quantified and converted to cDNA using reverse transcriptase, and diluted 1:10 in H2O. qPCR was performed using Bio-Rad iQ SYBR green super-mix (Bio-Rad, Hercules, CA, USA). The results were analyzed using delta-delta Ct calculations, normalized to Gapdh expression levels, and further normalized to the gene expression levels under vehicle control-treated conditions (error bars show standard deviations). Statistical significance was determined by T-test (critical value = 0.05), n = 3 replicate preparations. IL1α qPCR primers were from SABiosciences (Frederick, MD, USA). Additional qPCR primer sequences are as follows: Cdkn1a f-GACAAGAGGCCCAGTACTTCC, r-CAGACACCAGAGTGCAAGAC; Cdkn1b f-GGACTTGGAGAAGCACTGC, r-CACCTCCTGCCACTCGTATC; Cyp24a1 f-GAAGATGTGAGGAATATGCCCTATTT, r-CCGAGTTGTGAATGGCACACT; Gapdh f-TGCGACTTCAACAGCAACTC, r-GCCTCTCTTGCTCAGTGTCC.

shRNA targeting

shRNA vectors were generated as described in Sui and Shi [49]. The IL1α target site was GGTAGTGAGACCGACCTCATT. After infection with ecotropic virus, single cell clones were isolated using cloning cylinders, and IL1α protein expression was evaluated by Western blot after 24 hr treatments with 100 nM 1,25(OH)2D3 or 0.1% ethanol. Viral infection efficiency was validated by a positive GFP signal encoded by the virus.


Immunofluorescence was performed as described in [50]. Fluorescent signal images were captured using a Nikon DXM1200F digital camera on a Nikon Eclipse 50i microscope with an EXFO X-Cite 120 Fluorescence Illumination System.

Senescence-associated beta-galactosidase (SA-β-gal) assay

SA-β-gal activity was evaluated as described in Axanova et al.[51].


1,25(OH)2D3 inhibits mammary cell growth and induces p21 and p27

1,25(OH)2D3 has been shown to inhibit growth of benign and malignant breast epithelial cells [20,52,53]. We previously isolated normal MMECs from B1/6; 129/SVEV mice. A trypan blue exclusion assay revealed that 1,25(OH)2D3 elicited dose-dependent growth inhibition of MMECs at 48 hrs (Figure 1A). 1,25(OH)2D3 also inhibited clonogenic growth of MMECs (Figure 1B and C). These results verify the growth-suppressive effects of 1,25(OH)2D3 in normal MMECs. p21 and p27, encoded respectively by Cdkn1a and Cdkn1b, are common downstream targets of 1,25(OH)2D3 that contribute to cell cycle arrest in breast cancer cells [53,54]. qPCR showed a non-significant trend toward induction of Cdkn1a and significant induction of Cdkn1b mRNA after 48 hrs of 1,25(OH)2D3 in MMECs (Figure 2A). However, protein levels of p27 increased by 6 and 24 hours of 1,25(OH)2D3, while p21 protein induction was minimal (Figure 2B, Figure 1). These results were consistent in three experimental replicates; we speculate that the p21 expression is low in these cells, giving a generally weak signal by immunoblot which made quantification difficult. p21 and p27 can be regulated post-transcriptionally and post-translationally, so the disconnect between mRNA and protein expression patterns is likely due to unknown secondary regulation that may occur at earlier (6-24 hrs) versus later (48 hrs) time points [55-58]. Regardless, 1,25(OH)2D3 induced significant growth inhibition of MMECs that was consistent with p27 protein induction.

Figure 1. 1,25(OH)2D3 inhibits MMEC growth.

(A) MMECs were treated with the indicated doses of 1,25(OH)2D3 or 0.1% vehicle control (EtOH) for 48 hours. Viable cells were counted according to trypan blue exclusion. * = p < 0.05. (B) Representative images from clonogenic assays, quantified in (C). * = p < 0.05.

Figure 2. 1,25(OH)2D3 induces p27 in MMECs.

(A) qPCR indicated induction of Cdkn1b mRNA at 48 hrs of 100 nM 1,25(OH)2D3 (1,25D3, * = p < 0.05) and a non-significant trend toward induction of Cdkn1a at 48 hrs. (B) Induction of p27 protein was detected at 6 and 24 hrs of treatment with 100 nM 1,25(OH)2D3 (D) compared to EtOH control (E). The p21 antibody signal was weak.

1,25(OH)2D3 induces senescence in mammary epithelial cells

We previously reported that 1,25(OH)2D3 induces senescence in prostate cancer cell lines as well as in normal PrP/SC in dose-dependent manners [21,51]. We hypothesized that 1,25(OH)2D3 can induce senescence in mammary epithelial cells as well. We performed a senescence-associated beta galactosidase (SA-β-gal) assay in MMECs treated with vehicle control (0.1% ethanol) or increasing doses of 1,25(OH)2D3 every 48 hours for 96 hours. Senescent cells are characterized by an enlarged, flattened morphology and SA-β-gal expression. We found that 100 nM 1,25(OH)2D3 significantly induced MMEC senescence (Figure 3), indicating that induction of senescence by 1,25(OH)2D3 is not a prostate-specific effect. Induction of senescence may be considered one mode of 1,25(OH)2D3-mediated growth inhibition in both mammary and prostate cells.

Figure 3. 1,25(OH)2D3 induces senescence of MMECs.

(A) Representative images from the SA-β-gal assays quantified in (B). 100 nM 1,25(OH)2D3 significantly induced senescence compared to the control treatment (EtOH). Bars labeled “a” or “b” are statistically significantly different from each other according to ANOVA and post-hoc Fisher’s LSD test (n = 3 replicates, ~160 cells quantified in each of 10 fields of view per replicate, critical value = 0.05).

1,25(OH)2D3 induces IL1α in mammary epithelial cells

We previously identified IL1α as a novel, prominent downstream signaling target of 1,25(OH)2D3 in mouse PrP/SC. To test whether IL1α is a target of 1,25(OH)2D3 in mammary cells as well, we investigated its regulation in MMECs in response to 1,25(OH)2D3. qPCR data showed a 6-fold increase in IL1α mRNA by 24 hrs of exposure to 1,25(OH)2D3, which was sustained at 48 hr (Figure 4A). Immunoblot blot analysis revealed induction of IL1α protein at 6 hrs and more robust induction at 24 and 48 hrs. (Figure 4B, Figure 2). IL1α protein was virtually undetectable in the absence of 1,25(OH)2D3. We previously identified a putative vitamin D response element (VDRE) in the promoter region of IL1α that aligns with established VDREs in other targets of 1,25(OH)2D3 [21], so it is possible that IL1α is a direct transcriptional target of 1,25(OH)2D3. Together with our previous report we identify IL1α as a downstream target of 1,25(OH)2D3 in both mammary and prostate epithelial cells [21].

Figure 4. 1,25(OH)2D3 induces IL1α mRNA and protein in MMECs.

(A) qPCR revealed a 5 to 6-fold induction of IL1α mRNA by 100 nM 1,25(OH)2D3. * = p < 0.001. (B) 100 nM 1,25(OH)2D3 (D) induced IL1α protein at 6, 24, and 48 hours. Very little IL1α was present in the cells treated with ethanol control (E).

Cellular localization of IL1α and IL1R1 in mammary epithelial cells

IL1α is rarely secreted from epithelial cells [21,59], but it can be tethered to the cell membrane or shuttled to the nucleus via its nuclear localization sequence. This distinction is important because the cellular localization of IL1α likely determines its downstream effects [39]. We used immunofluorescence to visualize the cellular localization of IL1α in MMECs treated with 100 nM 1,25(OH)2D3 or vehicle control (0.1% ethanol) for 24 and 48 hrs. IL1α was localized to the nuclear and cytoplasmic compartments of MMECs treated with 100 nM 1,25(OH)2D3 for both 24 and 48 hours (Figure 5A, arrows). As expected, IL1α signal was not detected in the ethanol control-treated cells, nor was it detected under negative control conditions (no primary antibody, Figure 5A). The localization of 1,25(OH)2D3-induced IL1α mirrors that in the prostate stem cell [21] and suggests an intracrine function for IL1α in response to 1,25(OH)2D3.

Figure 5. Cellular localization of IL1α and IL1R1 in MMECs.

(A) Punctate IL1α signals (arrows) were detected in the nuclear and cytoplasmic compartments of MMECs upon 24 and 48 hr treatments with 100 nM 1,25(OH)2D3. IL1α was undetected in 0.1% vehicle control-treated cells (EtOH) and under negative control conditions (no primary antibody). (B) IL1RI signal was detected at the edges of the cell membranes at 24 and 48 hours in MMECs treated with 0.1% vehicle control (EtOH, arrows). IL1RI was detected both at the edges of the cells and within the cytoplasmic compartments after treatment with 100 nM 1,25(OH)2D3 for 48 hrs (arrows). No signal was detected under negative control conditions.

Previous reports have demonstrated cellular uptake and intracellular interaction of IL1R1 with IL1α [60,61]. In control-treated MMECs, we observed IL1RI signal at the edges of the cell membranes at both 24 and 48 hours (Figure 5B, arrows). Interestingly, in MMECs treated with 100 nM 1,25(OH)2D3, IL1RI appeared to be localized both at the edges of the membrane and in the cytoplasmic compartment, especially at 48 hours (Figure 5B, arrows). A similar pattern was observed in the prostate stem cell [21], which contributes to speculation that IL1α may interact with IL1RI and promote intracellular translocation. Further studies will be necessary to investigate a possible intracellular role of the IL1R1/ IL1α complex. To our knowledge, this is the first report showing endogenous expression patterns of IL1α and IL1RI in mammary epithelial cells, particularly in response to 1,25(OH)2D3.

IL1α is necessary for the anti-proliferative effects of 1,25(OH)2D3 in MMECs

Because IL1α is highly upregulated by 1,25(OH)2D3 in MMECs and is necessary for 1,25(OH)2D3-mediated growth inhibition of prostate stem cells, we hypothesized that IL1α contributes to the anti-proliferative effects of 1,25(OH)2D3 in MMECs. We infected MMECs with previously validated lentiviral shRNA vectors targeting IL1α or a scrambled control sequence. We selected clonal populations of shRNA-infected MMECs that achieved complete and stable knock down of IL1α. We validated the knock down of IL1α by Western blot in cells treated for 24 hrs with 0.1% ethanol control or 100 nM 1,25(OH)2D3. IL1α protein expression was induced by 1,25(OH)2D3 in the control-infected MMECs (shRNA NC), and it was absent in the IL1α shRNA-infected MMECs (Figure 6A).

Figure 6. IL1α mediates the anti-proliferative effects of 1,25(OH)2D3 in MMECs.

(A) Western blot for IL1α expression in MMEC clones (cl.) infected with IL1α shRNA or negative control shRNA (shRNA NC). E = 0.1% ethanol, D = 100 nM 1,25(OH)2D3. (B) 48 hr trypan blue exclusion assays in MMEC clones infected with IL1α shRNA or control shRNA. * = p < 0.05.

We next tested the effects of 1,25(OH)2D3 on cell growth and viability in the control and IL1α shRNA-infected MMECs. MMECs infected with control shRNA were growth-inhibited by 1,25(OH)2D3 in a dose-dependent manner as expected according to a 48 hr trypan blue exclusion assay (Figure 6B). However, IL1α shRNA-infected MMECs were resistant to the growth-inhibitory effects of 1,25(OH)2D3 (Figure 6B). This suggests that IL1α is necessary for the anti-proliferative effects of 1,25(OH)2D3 in MMECs. To verify that the IL1α knock-down clones otherwise remained responsive to 1,25(OH)2D3, we performed qPCR for Cyp24a1, a well-described universal target of 1,25(OH)2D3 (Figure 3). Cyp24a1 mRNA levels were robustly induced by 1,25(OH)2D3 in all MMEC clones, suggesting that 1,25(OH)2D3 signaling remained intact and that the anti-proliferative effects of 1,25(OH)2D3 are in fact dependent on the presence of IL1α.


While the anti-proliferative and pro-differentiation effects of 1,25(OH)2D3 have been characterized in breast cancer cells, few studies have focused on the effects of 1,25(OH)2D3 in normal mammary cells. Such studies are critical for gaining a better understanding of a mechanistic basis for chemoprevention by vitamin D3. Here we have shown that 1,25(OH)2D3 reduces normal MMEC proliferation and induces senescence. Furthermore, IL1α is necessary for the anti-proliferative effects of 1,25(OH)2D3 in MMECs, and it likely acts in cytoplasmic and/or nuclear compartments.

Others have begun to interrogate the genomic effects of 1,25(OH)2D3 in normal and malignant human mammary cells and in mouse mammary tumor cells, but we are the first to report IL1α as a target of 1,25(OH)2D3 signaling in mammary cells [19,62]. Microarray studies have revealed that 1,25(OH)2D3 regulates a wide variety of genes involved in innate immunity, differentiation, metabolism, and extracellular matrix remodeling. It appears that specific 1,25(OH)2D3 target genes vary with the cell lines, model systems, and microarray platforms used. Additional microarray analyses from normal and malignant breast cells and subsequent experimental validation of potential 1,25(OH)2D3 targets will help shed light on the mechanistic actions of 1,25(OH)2D3 in the breast, informing the use of vitamin D3 in preventative and clinical settings. While most studies on the mechanistic action of vitamin D3 focus on the metabolic intermediate 1,25(OH)2D3, some data from other tissues suggest that alternative metabolic intermediates are generated in vivo [63]. The generation of these intermediates may also be important for vitamin D3 action. However, the role of these intermediates in any biological process, including growth inhibition of mammary cells, is as yet undefined.

Some of the common downstream targets of 1,25(OH)2D3 signaling in breast cancer cells include BRCA1, p21, p53, cMYC, E-Cadherin, and Cyclin D1, which contribute to cell cycle arrest, differentiation, and, at times, apoptosis [20,52,64,65]. 1,25(OH)2D3 has also been reported to inhibit matrix metalloproteinase (MMP) and urokinase-type plamsinogen activator (uPA) production and enhance tissue inhibitors of matrix metalloproteinases (TIMPs), which may help impede breast cancer cell invasion and metastasis [66,67]. Induction of p27 by1,25(OH)2D3 may contribute to its anti-proliferative effects in MMECs. p27 is a well-characterized mediator of cell cycle arrest, and it has also been implicated in induction of senescence [68]. Interestingly, IL1α is also implicated in senescence in some cell types including HUVECs, prostate cells, and fibroblasts [35,36,38]. However, induction of senescence by 1,25(OH)2D3 persisted upon knockdown of IL1α, suggesting that other signaling targets, such as p27, are likely mediate 1,25(OH)2D3-induced senescence in MMECs (Figure 4). Reports in prostate cancer models suggest that reduction or inhibition of p27 blocks induction of senescence [68,69], and investigations into the precise roles of p27 and IL1α in senescence in multiple cell types are ongoing.

IL1α activity has previously been reported in breast cancer cells outside of the context of vitamin D3. In 1988, recombinant IL1α was first reported to inhibit growth of estrogen-dependent breast cancer cell lines MDA-MB-415 and MCF-7, but not that of hormone-independent breast cancer cell lines (HS-578-T and MDA-231) [27,70]. Later, IL1α was shown to inhibit estrogen-mediated growth and to decrease estrogen receptor levels in MCF-7 breast cancer cells [71], establishing an intersection between cytokine and hormonal signaling in mammary cells. Subsequent studies presented a correlation between IL1α expression, breast cancer severity, and ER-negativity [72,73], but no functional connections have been established.

Due to the expression of endogenous IL1RI in MMECs, we can interrogate whether recombinant IL1α is sufficient to inhibit MMEC growth, rescue 1,25(OH)2D3-mediated growth inhibition in IL1α knockdown cells, induce p27, and/or induce senescence. However, because intracellular IL1α in epithelial cells likely has a different mode of action from extracellular IL1α [39,59], we have also generated IL1α overexpression vectors with which to infect MMECs and IL1α knock-down MMECs in order to further elucidate the contributions of nuclear, membrane-bound, and secreted IL1α signaling in MMEC survival and proliferation. Whether knocking down IL1RI also attenuates the anti-proliferative effects of 1,25(OH)2D3 remains to be evaluated.

As approaches to breast cancer treatment become more complex, the importance of chemoprevention is increasingly evident. While in vitro studies have shown that estrogen receptor (ER)-positive breast cancer cell lines are directly growth-inhibited by 1,25(OH)2D3, ER-negative tumor invasion and angiogenesis are indirectly inhibited by 1,25(OH)2D3 [52,53]. However, 1,25(OH)2D3 may be more beneficial in the chemopreventative setting; it is thought to regulate differentiation and maintain mammary gland homeostasis in the presence of mitogenic signals from the microenvironment [53]. If 1,25(OH)2D3 signaling is lacking or impaired, estrogen-stimulated epithelial proliferation may escape regulatory control. Our study adds to those supporting the relevance of vitamin D3 as a chemopreventative agent, and we report a novel mechanistic role for IL1α in the 1,25(OH)2D3-mediated growth regulation of normal mammary epithelial cells.

Supporting Information

Figure S1.

Full scans of Western blots for p27, p21 (long exposure), and β actin (short exposure) from Figure 2. The p21 signal is weak.


Figure S2.

Full scan of Western blot for IL1α and β actin from Figure 4.


Figure S3.

IL1α knockdown cells are responsive to 1,25(OH)2D3. qPCR shows robust induction of Cyp24a1 by 100 nM 1,25(OH)2D3 (1,25D3) at 24 hrs in MMEC clones (cl.) infected with negative control (NC) and IL1α shRNA.


Figure S4.

1,25(OH)2D3 induces senescence in the absence of IL1α. Quantification of senescence-associated beta galactosidase assays revealed that 1,25(OH)2D3 significantly induced senescence compared to the control treatment (EtOH). Bars labeled “a,” “b,” or “c” are statistically significantly different from each other according to ANOVA and post-hoc Fisher’s LSD test (n = 3 replicates, ~160 cells quantified in each of 10 fields of view per replicate, critical value = 0.05).


Author Contributions

Conceived and designed the experiments: SLM SDC. Performed the experiments: SLM LS. Analyzed the data: SLM LS SDC. Contributed reagents/materials/analysis tools: SDC. Wrote the manuscript: SLM SDC.


  1. 1. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL et al. (2007) Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 103: 708-711. doi:10.1016/j.jsbmb.2006.12.007. PubMed: 17368188.
  2. 2. Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM et al. (1999) Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 2: 283-291. PubMed: 10512563.
  3. 3. Giovannucci E (2008) Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 624: 31-42. doi:10.1007/978-0-387-77574-6_3. PubMed: 18348445.
  4. 4. Krishnan AV, Swami S, Feldman D (2012) Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: Importance of mammary CYP27B1 for treatment and prevention. J Steroid Biochem Mol Biol.
  5. 5. Engel LS, Orlow I, Sima CS, Satagopan J, Mujumdar U et al. (2012) Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 21: 1856-1867. doi:10.1158/1055-9965.EPI-12-0551. PubMed: 22892281.
  6. 6. Yao S, Ambrosone CB (2012) Associations between vitamin D deficiency and risk of aggressive breast cancer in African-American women. J Steroid Biochem Mol Biol, 136: 337–41. PubMed: 22995734.
  7. 7. Yousef FM, Jacobs ET, Kang PT, Hakim IA, Going S et al. (2013) Vitamin D status and breast cancer in Saudi Arabian women: case-control study. Am J Clin Nutr, 98: 105–10. PubMed: 23697705.
  8. 8. Gulliford T, English J, Colston KW, Menday P, Moller S et al. (1998) A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 78: 6-13. doi:10.1038/bjc.1998.434. PubMed: 9662243.
  9. 9. Hansen CM, Hamberg KJ, Binderup E, Binderup L (2000) Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 6: 803-828. doi:10.2174/1381612003400371. PubMed: 10828309.
  10. 10. Mehta RG, Peng X, Alimirah F, Murillo G, Mehta R (2012) Vitamin D and breast cancer: Emerging concepts. Cancer Lett. PubMed: 23142286.
  11. 11. Lopes N, Paredes J, Costa JL, Ylstra B, Schmitt F (2012) Vitamin D and the mammary gland: a review on its role in normal development and breast cancer. Breast Cancer Res 14: 211. doi:10.1186/bcr3178. PubMed: 22676419.
  12. 12. Peppone L, Rickles A, Huston A, Sprod L, Hicks D et al. (2011) The Association between Prognostic Demographic and Tumor Characteristics of Breast Carcinomas with Serum 25-OH Vitamin D Levels. Cancer Epidemiol Biomarkers Prev 20: 717. doi:10.1158/1055-9965.EPI-11-0089.
  13. 13. Kemmis CM, Salvador SM, Smith KM, Welsh J (2006) Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136: 887-892. PubMed: 16549446.
  14. 14. Kemmis CM, Welsh J (2008) Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. J Cell Biochem 105: 980-988. doi:10.1002/jcb.21896. PubMed: 18767073.
  15. 15. Zinser GM, Welsh J (2004) Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. Mol Endocrinol 18: 2208-2223. doi:10.1210/me.2003-0469. PubMed: 15178742.
  16. 16. Zinser GM, Welsh J (2004) Effect of Vitamin D3 receptor ablation on murine mammary gland development and tumorigenesis. J Steroid Biochem Mol Biol 89-90: 433-436. doi:10.1016/j.jsbmb.2004.03.012. PubMed: 15225815.
  17. 17. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR et al. (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 51: 239-244. PubMed: 1846309.
  18. 18. Lopes N, Sousa B, Martins D, Gomes M, Vieira D et al. (2010) Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10: 483. doi:10.1186/1471-2407-10-483. PubMed: 20831823.
  19. 19. Matthews D, LaPorta E, Zinser GM, Narvaez CJ, Welsh J (2010) Genomic vitamin D signaling in breast cancer: Insights from animal models and human cells. J Steroid Biochem Mol Biol 121: 362-367. PubMed: 20412854.
  20. 20. Pendás-Franco N, González-Sancho JM, Suárez Y, Aguilera O, Steinmeyer A et al. (2007) Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75: 193-207. doi:10.1111/j.1432-0436.2006.00131.x. PubMed: 17288543.
  21. 21. Maund SL, Barclay WW, Hover LD, Axanova LS, Sui G et al. (2011) Interleukin-1 alpha mediates the anti-proliferative effects of 1,25 dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res.
  22. 22. Groves RW, Ross E, Barker JN, Ross JS, Camp RD et al. (1992) Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin. J Invest Dermatol 98: 384-387. doi:10.1111/1523-1747.ep12499816. PubMed: 1372029.
  23. 23. Warner RL, Paine R, Christensen PJ, Marletta MA, Richards MK et al. (1995) Lung sources and cytokine requirements for in vivo expression of inducible nitric oxide synthase. Am J Respir Cell Mol Biol 12: 649-661. doi:10.1165/ajrcmb.12.6.7539274. PubMed: 7539274.
  24. 24. Nam MJ, Thore C, Busija D (1995) Role of protein synthesis in interleukin 1 alpha-induced prostaglandin production in ovine astroglia. Prostaglandins Leukot Essent Fatty Acids 53: 69-72. doi:10.1016/0952-3278(95)90086-1. PubMed: 7675826.
  25. 25. Eller MS, Yaar M, Ostrom K, Harkness DD, Gilchrest BA (1995) A role for interleukin-1 in epidermal differentiation: regulation by expression of functional versus decoy receptors. J Cell Sci 108 ( 8): 2741-2746.
  26. 26. Fryling C, Dombalagian M, Burgess W, Hollander N, Schreiber AB et al. (1989) Purification and characterization of tumor inhibitory factor-2: its identity to interleukin 1. Cancer Res 49: 3333-3337. PubMed: 2785851.
  27. 27. Gaffney EV, Koch G, Tsai SC, Loucks T, Lingenfelter SE (1988) Correlation between human cell growth response to interleukin 1 and receptor binding. Cancer Res 48: 5455-5459. PubMed: 2970890.
  28. 28. Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N et al. (1998) Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 273: 8799-8805. doi:10.1074/jbc.273.15.8799. PubMed: 9535858.
  29. 29. Kilian PL, Kaffka KL, Biondi DA, Lipman JM, Benjamin WR et al. (1991) Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH:OVCAR-3). Cancer Res 51: 1823-1828. PubMed: 1825935.
  30. 30. Lader CS, Flanagan AM (1998) Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology 139: 3157-3164. doi:10.1210/en.139.7.3157. PubMed: 9645689.
  31. 31. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M et al. (1986) Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 29: 63-67. doi:10.1007/BF02427283. PubMed: 3514344.
  32. 32. Murai T, Nakagawa Y, Maeda H, Terada K (2001) Altered regulation of cell cycle machinery involved in interleukin-1-induced G(1) and G(2) phase growth arrest of A375S2 human melanoma cells. J Biol Chem 276: 6797-6806. doi:10.1074/jbc.M009355200. PubMed: 11098059.
  33. 33. Nalca A, Rangnekar VM (1998) The G1-phase growth-arresting action of interleukin-1 is independent of p53 and p21/WAF1 function. J Biol Chem 273: 30517-30523. doi:10.1074/jbc.273.46.30517. PubMed: 9804820.
  34. 34. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ (1985) Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 135: 3962-3968. PubMed: 2415593.
  35. 35. Castro P, Giri D, Lamb D, Ittmann M (2003) Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55: 30-38. doi:10.1002/pros.10204. PubMed: 12640658.
  36. 36. Orjalo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J (2009) Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A 106: 17031-17036. doi:10.1073/pnas.0905299106. PubMed: 19805069.
  37. 37. Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P et al. (2002) Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 277: 17154-17160. doi:10.1074/jbc.M112401200. PubMed: 11877436.
  38. 38. Garfinkel S, Brown S, Wessendorf JH, Maciag T (1994) Post-transcriptional regulation of interleukin 1 alpha in various strains of young and senescent human umbilical vein endothelial cells. Proc Natl Acad Sci U S A 91: 1559-1563. doi:10.1073/pnas.91.4.1559. PubMed: 8108444.
  39. 39. Apte RN, Dotan S, Elkabets M, White MR, Reich E et al. (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25: 387-408. doi:10.1007/s10555-006-9004-4. PubMed: 17043764.
  40. 40. Wessendorf JH, Garfinkel S, Zhan X, Brown S, Maciag T (1993) Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. J Biol Chem 268: 22100-22104. PubMed: 8408068.
  41. 41. Werman A, Werman-Venkert R, White R, Lee JK, Werman B et al. (2004) The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 101: 2434-2439. doi:10.1073/pnas.0308705101. PubMed: 14983027.
  42. 42. Buryskova M, Pospisek M, Grothey A, Simmet T, Burysek L (2004) Intracellular interleukin-1alpha functionally interacts with histone acetyltransferase complexes. J Biol Chem 279: 4017-4026. PubMed: 14612453.
  43. 43. Luheshi NM, McColl BW, Brough D (2009) Nuclear retention of IL-1 alpha by necrotic cells: a mechanism to dampen sterile inflammation. Eur J Immunol 39: 2973-2980. doi:10.1002/eji.200939712. PubMed: 19839011.
  44. 44. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC et al. (2001) IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7: 1812-1820. PubMed: 11410524.
  45. 45. Thorburn J, Moore F, Rao A, Barclay WW, Thomas LR et al. (2005) Selective inactivation of a Fas-associated death domain protein (FADD)-dependent apoptosis and autophagy pathway in immortal epithelial cells. Mol Cell Biol 16: 1189-1199. doi:10.1091/mbc.E04-10-0906. PubMed: 15635090.
  46. 46. Barclay WW, Cramer SD (2005) Culture of mouse prostatic epithelial cells from genetically engineered mice. Prostate 63: 291-298. doi:10.1002/pros.20193. PubMed: 15599944.
  47. 47. Wade WN, Willingham MC, Koumenis C, Cramer SD (2002) p27Kip1 is essential for the antiproliferative action of 1,25-dihydroxyvitamin D3 in primary, but not immortalized, mouse embryonic fibroblasts. J Biol Chem 277: 37301-37306. doi:10.1074/jbc.M204162200. PubMed: 12163488.
  48. 48. Barclay WW, Axanova LS, Chen W, Romero L, Maund SL et al. (2008) Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells 26: 600-610. doi:10.1634/stemcells.2007-0309. PubMed: 18055450.
  49. 49. Sui G, Shi Y (2005) Gene silencing by a DNA vector-based RNAi technology. Methods Mol Biol 309: 205-218. PubMed: 15990402.
  50. 50. Seals DF, Azucena EJ, Pass I, Tesfay L, Gordon R et al. (2005) The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell 7: 155-165. doi:10.1016/j.ccr.2005.01.006. PubMed: 15710328.
  51. 51. Axanova LS, Chen YQ, McCoy T, Sui G, Cramer SD (2010) 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate 70: 1658-1671. doi:10.1002/pros.21201. PubMed: 20583132.
  52. 52. Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S et al. (2001) 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat 67: 157-168. doi:10.1023/A:1010643323268. PubMed: 11519864.
  53. 53. Colston KW, Hansen CM (2002) Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9: 45-59. doi:10.1677/erc.0.0090045. PubMed: 11914182.
  54. 54. Narvaez CJ, Zinser G, Welsh J (2001) Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids 66: 301-308. doi:10.1016/S0039-128X(00)00202-6. PubMed: 11179738.
  55. 55. Park JS, Qiao L, Gilfor D, Yang MY, Hylemon PB et al. (2000) A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes. Mol Cell Biol 11: 2915-2932. doi:10.1091/mbc.11.9.2915.
  56. 56. Leung-Pineda V, Pan Y, Chen H, Kilberg MS (2004) Induction of p21 and p27 expression by amino acid deprivation of HepG2 human hepatoma cells involves mRNA stabilization. Biochem J 379: 79-88. doi:10.1042/BJ20031383. PubMed: 14715082.
  57. 57. Hirsch CL, Bonham K (2004) Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells. FEBS Lett 570: 37-40. doi:10.1016/j.febslet.2004.06.018. PubMed: 15251435.
  58. 58. Vervoorts J, Lüscher B (2008) Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci 65: 3255-3264. doi:10.1007/s00018-008-8296-7. PubMed: 18636226.
  59. 59. Cohen I, Rider P, Carmi Y, Braiman A, Dotan S et al. (2010) Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A 107: 2574-2579. doi:10.1073/pnas.0915018107. PubMed: 20133797.
  60. 60. Mizel SB, Kilian PL, Lewis JC, Paganelli KA, Chizzonite RA (1987) The interleukin 1 receptor. Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. J Immunol 138: 2906-2912. PubMed: 2952728.
  61. 61. Grenfell S, Smithers N, Miller K, Solari R (1989) Receptor-mediated endocytosis and nuclear transport of human interleukin 1 alpha. Biochem J 264: 813-822. PubMed: 2533500.
  62. 62. Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D (2003) Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat 80: 49-62. doi:10.1023/A:1024487118457. PubMed: 12889598.
  63. 63. Slominski AT, Kim TK, Shehabi HZ, Semak I, Tang EK et al. (2012) In vivo evidence for a novel pathway of vitamin D(3) metabolism initiated by P450scc and modified by CYP27B1. FASEB J 26: 3901-3915. doi:10.1096/fj.12-208975. PubMed: 22683847.
  64. 64. Lowe L, Hansen CM, Senaratne S, Colston KW (2003) Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Recent Results Cancer Res 164: 99-110. doi:10.1007/978-3-642-55580-0_6. PubMed: 12908448.
  65. 65. Welsh J (1994) Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 72: 537-545. doi:10.1139/o94-072. PubMed: 7654327.
  66. 66. Paduch R, Kandefer-Szerszeń M (2005) Vitamin D, tamoxifen and beta-estradiol modulate breast cancer cell growth and interleukin-6 and metalloproteinase-2 production in three-dimensional co-cultures of tumor cell spheroids with endothelium. Cell Biol Toxicol 21: 247-256. doi:10.1007/s10565-005-0002-z. PubMed: 16323060.
  67. 67. Koli K, Keski-Oja J (2000) 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 11: 221-229. PubMed: 10775039.
  68. 68. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM et al. (2008) A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14: 146-155. doi:10.1016/j.ccr.2008.06.002. PubMed: 18691549.
  69. 69. Ewald JA, Jarrard DF (2012) Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer. Transl Oncol 5: 278-287. PubMed: 22937180.
  70. 70. Paciotti GF, Tamarkin L (1988) Interleukin-1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro. Mol Endocrinol 2: 459-464. doi:10.1210/mend-2-5-459. PubMed: 2971135.
  71. 71. Danforth DN Jr., Sgagias MK (1991) Interleukin 1 alpha blocks estradiol-stimulated growth and down-regulates the estrogen receptor in MCF-7 breast cancer cells in vitro. Cancer Res 51: 1488-1493. PubMed: 1997187.
  72. 72. Singer CF, Hudelist G, Gschwantler-Kaulich D, Fink-Retter A, Mueller R et al. (2006) Interleukin-1alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity. Int J Gynecol Cancer 16 Suppl 2: 556-559. doi:10.1111/j.1525-1438.2006.00695.x. PubMed: 17010072.
  73. 73. Singer CF, Kronsteiner N, Hudelist G, Marton E, Walter I et al. (2003) Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 9: 4877-4883. PubMed: 14581361.